Struggling Swiss biotech Polyphor AG, which has suffered a string of setbacks in the clinic, has been handed a lifeline by negotiating a merger with EnBiotix, Inc. of the US, a privately held rare disease company, which is focused on cystic fibrosis.
The proposed deal with Enbiotix comes at the end of what Polyphor chairman Kuno Sommer described as "an extensive and...